These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1514881)

  • 21. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
    Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W
    J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonism of [3H]zacopride binding to 5-HT3 recognition sites by its (R) and (S) enantiomers.
    Pinkus LM; Sarbin NS; Gordon JC; Munson HR
    Eur J Pharmacol; 1990 Apr; 179(1-2):231-5. PubMed ID: 2364986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of zacopride, a moderate I
    Elnakish MT; Canan BD; Kilic A; Mohler PJ; Janssen PM
    Pharmacol Res; 2017 Jan; 115():309-318. PubMed ID: 27914945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The clinical development of an antiemetic in oncology. A meta-analysis].
    Pérez Campos A
    Med Clin (Barc); 1994 Sep; 103(8):281-6. PubMed ID: 7967877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interaction of R(+)- and S(-)-zacopride with PCPA to modify rodent aversive behaviour.
    Barnes NM; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):15-25. PubMed ID: 1356806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
    Chappell AS; Bay JM; Botzum GD; Cohen ML
    Neuropharmacology; 1994; 33(3-4):509-13. PubMed ID: 7984290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin antagonists: a new class of antiemetic agents.
    Hesketh PJ; Gandara DR
    J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain.
    Waeber C; Pinkus LM; Palacios JM
    Eur J Pharmacol; 1990 Jun; 181(3):283-7. PubMed ID: 2384135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zacopride: anxiolytic profile in rodent and primate models of anxiety.
    Costall B; Domeney AM; Gerrard PA; Kelly ME; Naylor RJ
    J Pharm Pharmacol; 1988 Apr; 40(4):302-5. PubMed ID: 2900320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-HT3 receptor antagonists attenuate cocaine-induced locomotion in mice.
    Reith ME
    Eur J Pharmacol; 1990 Sep; 186(2-3):327-30. PubMed ID: 2289534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
    Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
    J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissues.
    Kidd FJ; Levy JC; Nielsen M; Hamon M; Gozlan H
    Eur J Pharmacol; 1993 Sep; 247(1):45-56. PubMed ID: 8258360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.
    Barnes NM; Cheng CH; Costall B; Ge J; Naylor RJ
    Br J Pharmacol; 1992 Sep; 107(1):233-9. PubMed ID: 1384906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zacopride and BRL 24924 induce an increase in EEG-energy in rats.
    Boddeke HW; Kalkman HO
    Br J Pharmacol; 1990 Oct; 101(2):281-4. PubMed ID: 2257436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced anxiolytic effect of zacopride enantiomers in diazepam-withdrawn rats.
    File SE; Andrews N
    Eur J Pharmacol; 1993 Jun; 237(1):127-30. PubMed ID: 8102974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [3H]zacopride binding to 5-hydroxytryptamine3 sites on partially purified rabbit enteric neuronal membranes.
    Gordon JC; Barefoot DS; Sarbin NS; Pinkus LM
    J Pharmacol Exp Ther; 1989 Dec; 251(3):962-8. PubMed ID: 2600824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative autoradiographic mapping of 5-HT3 receptors in the rat CNS using [125I]iodo-zacopride and [3H]zacopride as radioligands.
    Laporte AM; Koscielniak T; Ponchant M; Vergé D; Hamon M; Gozlan H
    Synapse; 1992 Apr; 10(4):271-81. PubMed ID: 1585260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of 5-hydroxytryptamine3 receptors prevents cisplatin-induced but not motion- or xylazine-induced emesis in the cat.
    Lucot JB
    Pharmacol Biochem Behav; 1989 Jan; 32(1):207-10. PubMed ID: 2734331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
    Barnes JM; Barnes NM
    Biochem Pharmacol; 1993 May; 45(10):2155-8. PubMed ID: 8390263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells.
    Bolaños FJ; Schechter LE; Miquel MC; Emerit MB; Rumigny JF; Hamon M; Gozlan H
    Biochem Pharmacol; 1990 Oct; 40(7):1541-50. PubMed ID: 2222509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.